Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis
Status:
Completed
Trial end date:
2018-05-24
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies how well imetelstat sodium works in treating participants
with primary or secondary myelofibrosis and other myeloid malignancies. Imetelstat sodium may
stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Phase:
Phase 2
Details
Lead Sponsor:
Geron Corporation Janssen Research & Development, LLC